Q4 2018 13F Holders as of 12/31/2018
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
55.2M
-
Number of holders
-
111
-
Total 13F shares, excl. options
-
27.8M
-
Shares change
-
-1.15M
-
Total reported value, excl. options
-
$261M
-
Value change
-
-$17M
-
Put/Call ratio
-
0
-
Number of buys
-
47
-
Number of sells
-
-55
-
Price
-
$9.40
Significant Holders of Voyager Therapeutics, Inc. - Common Stock, $0.001 par value (VYGR) as of Q4 2018
138 filings reported holding VYGR - Voyager Therapeutics, Inc. - Common Stock, $0.001 par value as of Q4 2018.
Voyager Therapeutics, Inc. - Common Stock, $0.001 par value (VYGR) has 111 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27.8M shares
of 55.2M outstanding shares and own 50.34% of the company stock.
Largest 10 shareholders include TRV GP III, LLC (6.39M shares), BB BIOTECH AG (2.87M shares), ARMISTICE CAPITAL, LLC (2.84M shares), BlackRock Inc. (1.86M shares), Vanguard Group Inc (1.38M shares), HIGHLINE CAPITAL MANAGEMENT, L.P. (1.28M shares), Casdin Capital, LLC (1.13M shares), FMR LLC (911K shares), FARALLON CAPITAL MANAGEMENT LLC (909K shares), and WELLINGTON MANAGEMENT GROUP LLP (492K shares).
This table shows the top 111 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.